Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 2/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3271255 | 0.89 | CYP1A2 (0.39) | SSTR4CHRM2CHRM1EPHX1CHRM4 | |
| SCHEMBL8737253 | 0.86 | NAAA (0.41) | CCR2EPHX1NAAA | |
| SCHEMBL8737270 | 0.86 | NAAA (0.41) | CCR2EPHX1NAAA | |
| SCHEMBL8735270 | 0.86 | NAAA (0.41) | CCR2EPHX1NAAA | |
| SCHEMBL2344965 | 0.84 | RECQL (0.37) | SSTR4CHRM2CHRM1EPHX1CHRM4 | |
| SCHEMBL28511208 | 0.84 | CCR2 (0.40) | CCR2EPHX1NAAA | |
| SCHEMBL27775281 | 0.83 | ARG1 (0.40) | CCR2EPHX1CYP2D6 | |
| SCHEMBL27576639 | 0.81 | LMNA (0.36) | SSTR4CCR2EPHX1KDM4EALDH1A1 | |
| SCHEMBL11323557 | 0.80 | ALDH1A1 (0.40) | SSTR4EPHX1ALDH1A1CYP1A2SMN1; SMN2 | |
| SCHEMBL28103582 | 0.80 | EPHX1 (0.35) | SSTR4CHRM2CHRM1EPHX1CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1200703-C | Use of pentanoate derivant | ONO PHARMACEUTICAL CO (JP) | 2005-05-11 | — | — | CN | claimed |
| US-20040248762-A1 | Malodor counteractant compositions | MCGEE THOMAS (US) | 2004-12-09 | — | — | US | claimed |
| EP-1345883-A1 | MALODOR COUNTERACTANT COMPOSITIONS | Givaudan SA (CH) | 2003-09-24 | — | — | EP | claimed |
| US-20030008787-A1 | Malodor counteractant compositions | GIVAUDAN SA | 2003-01-09 | — | — | US | claimed |
| WO-2002051788-A1 | MALODOR COUNTERACTANT COMPOSITIONS | GIVAUDAN SA (CH) | 2002-07-04 | — | — | WO | claimed |
| CN-1322524-A | Use of pentanoate derivant | ONO PHARMACEUTICAL CO (JP) | 2001-11-21 | — | — | CN | claimed |
| CN-114901901-A | Fabric spray | 联合利华知识产权控股有限公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-114174584-A | Fabric spray composition | 联合利华知识产权控股有限公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-1345883-B1 | MALODOR COUNTERACTANT COMPOSITIONS | GIVAUDAN SA (CH) | 2010-02-17 | — | — | EP | disclosed |
| US-7332462-B2 | Malodor counteractant compounds | GIVAUDAN SA (CH) | 2008-02-19 | — | — | US | disclosed |
| US-7288507-B2 | Malodor counteractant compounds | GIVAUDAN SA (CH) | 2007-10-30 | — | — | US | disclosed |
| US-20070116655-A1 | MALODOR COUNTERACTANT COMPOUNDS | GIVAUDAN SA (CH) | 2007-05-24 | — | — | US | disclosed |
| US-20060034789-A1 | Malodor counteractant compounds | GIVAUDAN SA (CH) | 2006-02-16 | — | — | US | disclosed |
| CN-1200703-C | Use of pentanoate derivant | ONO PHARMACEUTICAL CO (JP) | 2005-05-11 | — | — | CN | disclosed |
| US-20040248762-A1 | Malodor counteractant compositions | MCGEE THOMAS (US) | 2004-12-09 | — | — | US | disclosed |
| EP-1345883-A1 | MALODOR COUNTERACTANT COMPOSITIONS | Givaudan SA (CH) | 2003-09-24 | — | — | EP | disclosed |
| US-6610648-B2 | Alkyl 3-phenylprop-2-enoic acid ester derivatives | GIVAUDAN SA (CH) | 2003-08-26 | — | — | US | disclosed |
| US-20030008787-A1 | Malodor counteractant compositions | GIVAUDAN SA | 2003-01-09 | — | — | US | disclosed |
| WO-2002051788-A1 | MALODOR COUNTERACTANT COMPOSITIONS | GIVAUDAN SA (CH) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248762-A1 | Malodor counteractant compositions | MAL2, OPRM1, OR51E2 | SSTR4 2374/4885CCR2 608/4885CHRM2 198/4885 |
| US-20060034789-A1 | Malodor counteractant compounds | MAL2, OR51E2, OPRM1 | SSTR4 1059/4885CCR2 472/4885CHRM2 111/4885 |
| US-20070116655-A1 | MALODOR COUNTERACTANT COMPOUNDS | MAL2, OR51E2, OPRM1 | SSTR4 1129/4885CCR2 551/4885CHRM2 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.